GlassScriptPhysician profile
Tagbo Ekwonu
NPI 1093890535
$20,182.13
in general payments reported to CMS, 2019-2025
34 companies · $2,581 in 2025
The $2,581 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,476 · 2020: $1,900 · 2021: $2,368 · 2022: $2,643 · 2023: $3,203 · 2024: $5,011 · 2025: $2,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,954 · Consulting Fee: $1,620 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200 · Education: $21.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,954.01 |
| Consulting Fee | $1,620.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
| Education | $21.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $7,191.03 | 2019-2025 | Biktarvy, Epclusa |
| Viiv Healthcare Company | $5,037.62 | 2019-2025 | Cabenuva, Dovato, Apretude |
| Janssen Biotech, INC. | $1,484.61 | 2019-2023 | Symtuza |
| Astrazeneca Pharmaceuticals LP | $1,101.08 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $692.63 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Abbott Laboratories | $502.80 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $484.95 | 2019-2025 | |
| Theratechnologies INC. | $445.88 | 2019-2025 | Egrifta, Trogarzo |
| Pfizer INC. | $403.60 | 2019-2025 | |
| Janssen Products, LP | $370.89 | 2019-2022 | |
| Amgen INC. | $288.87 | 2024-2025 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $218.89 | 2019-2020 | |
| Eko Health, INC. | $200.00 | 2024 | |
| Cranial Technologies, INC | $194.88 | 2019-2025 | Doc Band |
| Novo Nordisk INC | $192.72 | 2022-2025 | Wegovy, Rybelsus |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $191.04 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $183.94 | 2024-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $149.57 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $135.48 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $121.83 | 2023 | Onpattro |
| Napo Pharmaceuticals INC | $120.78 | 2019 | |
| Horizon Therapeutics Plc | $94.31 | 2023 | Krystexxa |
| Corcept Therapeutics | $68.57 | 2023-2024 | Korlym |
| Allergan, INC. | $59.31 | 2020 | |
| Hologic Sales and Service, LLC | $46.93 | 2022-2025 | Aptima, Thinprep 2000 Processor |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.41 | 2020-2021 | |
| Janssen Scientific Affairs, LLC | $32.72 | 2021 | |
| Mylan Pharmaceuticals INC. | $22.66 | 2019 | |
| Seqirus USA INC | $21.06 | 2025 | Fluad, Flucelvax |
| Mylan Institutional INC. | $18.97 | 2019 | |
| Paratek Pharmaceuticals, INC. | $18.71 | 2019 | |
| Shield Therapeutics INC | $16.67 | 2023 | Accrufer |
| Genentech USA, INC. | $11.97 | 2019 | |
| Eisai INC. | $11.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tagbo Ekwonu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.